Sign in

    Douglas Macpherson

    Research Analyst at Mizuho Securities

    Douglas Macpherson is an Equity Research Associate specializing in healthcare at H.C. Wainwright & Co., where he has covered innovative biotechnology and pharmaceutical companies since April 2023. He leverages his scientific background, including a PhD in Biochemistry from the City University of New York, to analyze firms advancing cancer therapeutics and biomaterials. Prior to joining H.C. Wainwright, Macpherson contributed to research and business development initiatives at Biogelx Ltd. and Stevens Institute of Technology, and held research positions at Yale School of Medicine and CUNY, giving him a diverse analytical and technical foundation. He holds advanced credentials in biochemistry and biotechnology, though there is no available evidence of FINRA or securities licensing, and quantitative performance metrics are not publicly disclosed.

    Douglas Macpherson's questions to Alector (ALEC) leadership

    Douglas Macpherson's questions to Alector (ALEC) leadership • Q2 2025

    Question

    Douglas Macpherson of Mizuho Securities asked what measures were taken in the INFRONT3 trial to minimize a potential placebo effect on subjective clinical endpoints. He also inquired about the risk of ARIA-E (amyloid-related imaging abnormalities) side effects.

    Answer

    CMO Giacomo Salvadore explained that the trial's powering accounts for placebo effects, which tend to dissipate over the 96-week study duration in neurodegenerative diseases. He confirmed there have been no reports of ARIA in the study, noting the biological mechanism for ARIA (amyloid removal) is not relevant to FTD-GRN.

    Ask Fintool Equity Research AI

    Douglas Macpherson's questions to X4 Pharmaceuticals (XFOR) leadership

    Douglas Macpherson's questions to X4 Pharmaceuticals (XFOR) leadership • Q4 2024

    Question

    Douglas Macpherson from H.C. Wainwright asked for commentary on commercialization learnings, whether new patients beyond the trial cohort are on therapy, details on ex-U.S. partnership milestones, and current patient population estimates for WHIM and chronic neutropenia.

    Answer

    Mark Baldry (Executive) confirmed that all U.S. trial patients are on commercial product and new demand is building through physician engagement. Paula Ragan (Executive) noted the next key ex-U.S. milestone is a potential EU approval in H1 2026 and reiterated patient estimates of ~1,000 diagnosed WHIM patients and a target of 15,000 severe CN patients in the U.S.

    Ask Fintool Equity Research AI

    Douglas Macpherson's questions to Quantum-Si (QSI) leadership

    Douglas Macpherson's questions to Quantum-Si (QSI) leadership • Q4 2024

    Question

    Douglas Macpherson asked if the sales cycle cadence is becoming more predictable with experience. He also inquired about the largest target markets, potential untapped opportunities, and the progress of the internal commercial team expansion, including their training status and expected impact.

    Answer

    President and CEO Jeffrey Hawkins acknowledged that the sales cycle is now more consistent and predictable, though it remains elongated compared to historical industry norms for similar instruments. He highlighted that the customer base is now evenly split between academic and other segments (pharma, biotech, government) and identified the international market as the most significant untapped opportunity. Hawkins confirmed the internal commercial team is staffed as planned, with most reps now active in their territories, and expects their impact, synergistic with the Avantor partnership, to become more apparent in the second half of 2025.

    Ask Fintool Equity Research AI